Product Description
Mechanisms of Action: RTK Inhibitor,C-Met Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer
Phase 1: Oncology Unspecified|Head and Neck Cancer|Healthy Volunteers|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2015-002070-21 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2019-01-02 |
|
| NCT00679133 | P1 |
Completed |
Oncology Unspecified |
2011-03-01 |
|
| NCT00697632 | P1 |
Completed |
Head and Neck Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Small Cell Lung Cancer |
2018-09-01 |
18% |
| NCT00975767 | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2013-07-01 |
|
| NCT01930006 | P1 |
Completed |
Oncology Unspecified|Healthy Volunteers |
2013-12-01 |
|
| NCT02544633 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2018-04-30 |
12% |
| MRTX-500 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2021-11-04 |
43% |